VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer.

ABSTRACT: To date, anti-CTLA-4 (ipilimumab) or anti-PD-1 (nivolumab) monotherapy has not been demonstrated to be of substantial clinical benefit in patients with prostate cancer. To identify additional immune-inhibitory pathways in the prostate-tumor microenvironment, we evaluated untreated and ipilimumab-treated tumors from patients in a presurgical clinical trial. Levels of the PD-L1 and VISTA inhibitory molecules increased on independent subsets of macrophages in treated tumors. Our data suggest that VISTA represents another compensatory inhibitory pathway in prostate tumors after ipilimumab therapy.

SUBMITTER: Gao J 

PROVIDER: S-EPMC5466900 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature